Tools
You do not have to make sense of everything alone.
Seven tools help you organize, check, and question the information in front of you, from record completeness to a doctor-ready question list.
Choose one
A tool for each step
Each card shows what the tool produces. These tools organize and check information; none diagnoses, determines medical eligibility, or predicts an outcome.
Mark the documents you hold, then get a list of what to request from the facility.
Medical-record completeness checker
See what you already have and what may still be missing.
Buka alatA guided search with clear filters and a criteria summary for each study.
Clinical trial finder
Explore studies by cancer, biomarker, and country before contacting anyone.
Buka alatQuestions about drugs, administration, monitoring, and insurer coverage.
Treatment cost question builder
Break cost questions into components without inventing a price.
Buka alatQuestions by cancer type and focus, ready to copy or print.
Questions for my doctor
Arrive at the consultation with a question list ready to use.
Buka alatCompare service focus and verification status across several facilities.
Facility capability finder
Compare facilities by recorded services, not partnership claims.
Buka alatOpen each result for its meaning, limits, related tests, and related studies.
Biomarker explorer
Understand what a biomarker result means and what it does not establish.
Buka alatExplore treatments by cancer and category, with recorded biomarker links.
Treatment category explorer
Learn treatment categories so terms in a report are easier to read.
Buka alat
One clearly recorded step is often more useful than trying to understand everything at once.
Step by step
If you are unsure where to begin, follow six steps for a second opinion: collect records, request copies, write questions, choose a reviewer, send the request, and follow up.
Open the second-opinion checklistStructured case tools
The twelve-step intake, Cancer Passport, and My Choices turn the records you have into a structured case summary. All three begin through the report-upload flow.
Open report intakeNot a diagnosis and not final medical advice. Must be reviewed by a doctor.
Next steps
These suggestions come from links between entries in TanyaKanker's database, not from a medical judgement. Each suggestion includes why it appears.
Next to learn
- Lung Cancer
Cancer type
Reason: Most connected in the oncology graph
- Stomach Cancer
Cancer type
Reason: Most connected in the oncology graph
- Lymphoma
Cancer type
Reason: Most connected in the oncology graph
- Multiple Myeloma
Cancer type
Reason: Most connected in the oncology graph
- ALK
Biomarker
Reason: Highest discovery priority among markers
- BCMA
Biomarker
Reason: Highest discovery priority among markers
- BCR-ABL
Biomarker
Reason: Highest discovery priority among markers
- BRAF
Biomarker
Reason: Highest discovery priority among markers
To check
- Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
NCT03191149 - Phase 2
Reason: Registry update in the last 30 days (2026-10-15)
- A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
NCT03460977 - Phase 1
Reason: Registry update in the last 30 days (2026-10-15)
- Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
NCT04267848 - Phase 3
Reason: Registry update in the last 30 days (2026-10-15)
- Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)
NCT04301076 - Phase 1
Reason: Registry update in the last 30 days (2026-10-15)
What you can do
- Upload medical reports
Build a case summary in twelve steps
Reason: Often the most useful next step after reading this page
- Request a second opinion
Review of the treatment plan
Reason: Relevant when a treatment plan is being considered
- Consult a navigator
A request is recorded with this page context
Reason: For asking the next step directly
Recently updated
- Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
NCT03191149 - Phase 2
Date: Registry update in the last 30 days (2026-10-15)
- A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
NCT03460977 - Phase 1
Date: Registry update in the last 30 days (2026-10-15)
- Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
NCT04267848 - Phase 3
Date: Registry update in the last 30 days (2026-10-15)
- Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)
NCT04301076 - Phase 1
Date: Registry update in the last 30 days (2026-10-15)
Want to follow changes on this topic? Save the page or follow the topic so it is easy to find again. View saved items.